Tyme Technologies, Inc., a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-461-2315
Debt
Current Ratio6.82
Quick Ratio6.82
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book12.96
Profitability
Net Income$-18,960,000.00
Net MarginsN/A
Return on Assets-106.20%
Miscellaneous
EmployeesN/A
OptionableOptionable
Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions
What is Tyme Technologies' stock symbol?
Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."
How were Tyme Technologies' earnings last quarter?
Tyme Technologies Inc (NASDAQ:TYME) announced its quarterly earnings data on Monday, November, 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.01. View Tyme Technologies' Earnings History.
When is Tyme Technologies' next earnings date?
What price target have analysts set for TYME?
2 brokerages have issued 12-month price objectives for Tyme Technologies' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Tyme Technologies' stock price to reach $10.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View Analyst Price Targets for Tyme Technologies.
What is the consensus analysts' recommendation for Tyme Technologies?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.
What are Wall Street analysts saying about Tyme Technologies stock?
Here are some recent quotes from research analysts about Tyme Technologies stock:
- 1. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (1/10/2019)
- 2. HC Wainwright analysts commented, "We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030 assuming a 12% discount rate and 2% terminal growth rate." (11/7/2018)
- 3. Canaccord Genuity analysts commented, "We continue to view SM-88’s ability to generate responses across ~15 solid and liquid tumor types and with durable effect in advanced cancer patients progressing on available therapies as intriguing and reiterate our BUY rating." (6/15/2018)
Has Tyme Technologies been receiving favorable news coverage?
News coverage about TYME stock has been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tyme Technologies earned a coverage optimism score of 1.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the immediate future.
Are investors shorting Tyme Technologies?
Tyme Technologies saw a increase in short interest in December. As of December 31st, there was short interest totalling 7,718,246 shares, an increase of 103.7% from the December 14th total of 3,789,460 shares. Based on an average daily volume of 1,496,507 shares, the short-interest ratio is presently 5.2 days. Currently, 19.3% of the company's shares are short sold. View Tyme Technologies' Current Options Chain.
Who are some of Tyme Technologies' key competitors?
Some companies that are related to Tyme Technologies include Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM), Retrophin (RTRX), Deciphera Pharmaceuticals (DCPH), Tricida (TCDA), Puma Biotechnology (PBYI), Homology Medicines (FIXX), Apellis Pharmaceuticals (APLS), Inflarx (IFRX), Lexicon Pharmaceuticals (LXRX), ImmunoGen (IMGN), Alder Biopharmaceuticals (ALDR), Epizyme (EPZM), AC Immune (ACIU) and Athenex (ATNX).
Who are Tyme Technologies' key executives?
Tyme Technologies' management team includes the folowing people:
- Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 55)
- Mr. Ben R. Taylor, Pres & CFO (Age 41)
- Mr. Michael S. Demurjian, Exec. VP, COO & Director (Age 51)
- Dr. Jonathan M. Eckard, Chief Scientific Affairs Officer (Age 44)
- Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 54)
How do I buy shares of Tyme Technologies?
Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tyme Technologies' stock price today?
One share of TYME stock can currently be purchased for approximately $3.50.
How big of a company is Tyme Technologies?
Tyme Technologies has a market capitalization of $253.85 million. The company earns $-18,960,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.
What is Tyme Technologies' official website?
How can I contact Tyme Technologies?
Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]
MarketBeat Community Rating for Tyme Technologies (NASDAQ TYME)
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
